Page 1of 44
a [COMPANY_001] company
Title:
Clinical Performance of a Silicone Hydr ogel for Daily Disposable Wear
Protocol Number:
Sponsor Name [CONTACT_13311]:
Test Product (s):CLE383-C 003 / [STUDY_ID_REMOVED]  
Alcon Research, Ltd.
[ADDRESS_582962] Lenses (DD T2 Contact 
[CONTACT_32993])
Investigator Agreement: I have read the clinical study  described herein, recognize its 
confidentiality , and agree to conduct the described trial in 
compliance with Good Clinical Practice (GCP), the ethical 
principles contained within the Declaration of Helsinki, this 
protocol, and all applicable regulatory  requirements. 
Additionally , I will comply  with all procedures for data 
record ing and reporting, will permit monitoring, auditing, and 
inspection of my  research center, and will retain all records 
until notified by  [CONTACT_1034].
Principal I nvestigator:
Signature [CONTACT_13312] :
[Include professional 
position ][May be entered into the document or written/t yped in later ]
Address:
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582963] Le nses ( D D T 2) 
Na me of C o ntr ol Pr o d uct C o o per V isi o n ®M y D a y ®(ste nfilc o n A) Dail y Dis p osa ble 
C o ntact Le nses (M Y D A Y )
Title of Trial Cli nical Perf or ma nce of a Silic o ne H y dr o gel f or Dail y  
Dis p osa ble Wear 
Pr ot oc ol N u m ber C L E 3 8 3 -C 0 0 3 
N u m ber of Sites 
C o u ntr y ~ 3 
U S 
Pla n ne d D urati o n of 
E x p os ure ~ 1 2 d a y s t otal d urati o n 
Test Pr o d uct: 6 da y s ( ± 1 da y )
C o ntr ol Pr o d uct: 6 da y s ( ± 1 da y )
N u m ber of S u bjects Tar get t o c o m plete: 4 4 
Pla n ne d t o e nr oll: ~ [ADDRESS_582964] le ns 
wearers (e xcl u di n g pre vi o us or c urre nt M Y D A Y wearers), 
ha ve at least [ADDRESS_582965] le nses i n a p o wer ra n ge fr o m -1. 5 0 D 
t o -4. 0 0 D. 
O bjecti ve (s) T he pri mar y  o bjecti ve of t his st u d y  is t o de m o nstrate 
n o ni nferi orit y  i n vis ual ac uit y  of D D T 2 w he n c o m pare d t o 
M Y D A Y . 
 
 
E n d p oi nts Pri mar y  Effecti ve ness 
Vis ual ac uit y Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 3of 4 4 
Safet y 
A Es 
De vice deficie ncies 
Bi o micr osc o p y
Assess me nts Effecti ve ness 
V A ( S nelle n dista nce )



  

  Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 4of 4 4 
Safet y 
A Es 
De vice deficie ncies 
Bi o micr osc o p y
St u d y  Desi g n Pr os pecti ve Si n gle -mas ke d 
(trial s u bject) 
Si n gle -mas ke d 
(I n vesti gat or) 
D o u ble- mas ke d 
O pe n -la be l
Ot her Si n gle gr o u p 
Parallel gr o u p 
Cr oss o ver 
Ot her 
C o ntralateral 
Bilateral 
M o n oc ular le ns wear Ra n d o mize d 
Test Pr o d uct Details Pri mar y  
c o m p o ne nt/ material 
Pr o d uct Na me D D T [ADDRESS_582966] urer Alc o n 
Ot her T he le nses will be a vaila ble i n 
-1. 5 0 D t o -4. 0 0 D ( 0. 2 5 D 
ste ps) 
C o ntr ol Pr o d uct Details Pri mar y  
c o m p o ne nt/ material ste nfilc o n A
Pr o d uct Na me M Y D A Y 
Ma n ufact urer C O O P E R VI SI O N 
Ot her T he le nses will be a vaila ble 
i n - 1. 5 0 D t o -4. 0 0 D ( 0. 2 5 D 
ste ps) 
I n cl usi o n Criteria 1. S u bject m ust be at least [ADDRESS_582967] 3 m o nt hs. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_582968] cy linder ≤ 0.75 D in each ey e.
5.BCVA 20/25 or better in each ey e.
Exclusion Criteria 1.Any anterior segment infection, inflammation, or 
abnormality  or disease (including s ystemic) that 
contraindicates contact [CONTACT_13279], as determined by  [CONTACT_3786].
2.Any use of s ystemic or ocular medications for which 
contact [CONTACT_456096], as 
determined b y the I nvestigator.
3.History  of refractive surgery  or plan to have refractive 
surgery  during the study  or irregular cornea in either ey e.
4.Ocular or intraocular surgery  (excluding placement of 
punctal plugs) within t he previous 12 months or planned 
during the stud y.
5.Biomicroscop y findings at screening that are moderate 
(Grade 3) or higher and/or corneal vascularization that is 
mild ( Grade 2) or higher.
6.Current or history  of pathologicall y dry eye in either ey e 
that, in the opi[INVESTIGATOR_2511] I nvestigator, would preclude 
contact [CONTACT_13279].
7.Current or history  of herpetic keratitis in either eye.
8.Eye injury  in either ey e within twelve weeks 
immediately  prior to enrollment for this trial.
9.Any previous or current wear of MYDAY.
10.Habitually  wearing monovision or multifocal lenses 
during the last [ADDRESS_582969] lenses in an extended wear 
modality  (routinel y sleepi[INVESTIGATOR_13261] 1 night 
per week) over the last [ADDRESS_582970] lens wear.
14.The Investigator, his/her staff, famil y members of the 
Investigator, famil y members of the Investigator’s staff, 
or individuals living in the households of the 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582971] i n a cli nical trial wit hi n t he 
pre vi o us 3 0 da y s or c urre ntl y  e nr olle d i n a n y cli nical 
trial. 
Ass ociate d Materials L u bricati o n/re -wetti n g dr o ps will n ot be per mitte d. 
Ta ble 1- [ADDRESS_582972] u d y Pr oce d ur es a n d Assess me nts 
Pr oce d ure/ Assess me nt Visit 1, D a y 1: 
B aseli ne/ Dis pe nse 
St u d y Le ns 1 Visit 2, Wee k 1: 
6 D a ys (± 1d a y ) 
F oll o w -u p St u d y 
Le ns 1 / Dis pe nse 
St u d y Le ns 2 Visit 3, Wee k 2: 
6 D a ys ( ± 1D a y ) 
F oll o w -u p St u d y 
Le ns 2 / E xit 
I n f or me d C o nse nt  - -
De m o gra p hics  - -
Me dical Hist or y  - -
C o nc o mita nt Me dicati o ns   
I n cl usi o n/ E xcl usi o n  - -
Ha bit ual le ns 
( bra n d, p o wer)  - -
V A w/ ha bit ual c orrecti o n 
(O D, O S, S nelle n dista nce)   
Bi o micr osc o p y   
Dis pe nse st u d y  le nses   -
V A w/ st u d y le nses (O D, 
O S, S nelle n dista nce 1)  Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 7of 4 4 
Pr oce d ure/ Assess me nt Visit 1, D a y 1: 
B aseli ne/ Dis pe nse 
St u d y Le ns 1 Visit 2, Wee k 1: 
6 D a ys (± 1d a y ) 
F oll o w -u p St u d y 
Le ns 1 / Dis pe nse 
St u d y Le ns 2 Visit 3, Wee k 2: 
6 D a ys ( ± 1D a y ) 
F oll o w -u p St u d y 
Le ns 2 / E xit 
A E s   
De vice deficie ncies   
E xit F or m () () ()
() assess me nt perf or me d as necessar y , e g, decrease of V A b y [ADDRESS_582973] (I P) 
1Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_582974] corrected visual acuity
CFR Code of Federal Regulations
D Diopter(s)
DD Daily disposable
DD T2 Daily Disposable T2 Soft Contact [CONTACT_456097] ’s brochure
ICF Informed consent form
IEC Independent ethics committee
IP Investigational product
IRB Institutional review board
ISO International Organization for Standardization
LogMAR Logarithm of the minimum angle of resolution
mm Millimeter
MYDA Y COOPER VISION M YDAY (stenfilcon A) Daily  Disposable Contact 
[CONTACT_32993]
N/A Not applicable
OD Right ey e
OS Left ey e
OU Both ey es
PP Per protocol
pt Point
Rx Prescription
SAE Serious adverse event
SADE Serious adverse device effect
SiHy Silicone hy drogel
US [LOCATION_002]
[LOCATION_003]DE Unanticipated serious adverse device ef fect
VA Visual acuity
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582975] Population .............................................................................................13
3.5 Outline of Study ................................................................................................14
4TREA TMENTS ADMINISTERED ...................................................................................14
4.1 Identity  of Study  Treatments .............................................................................14
4.2 Accountability  Procedures .................................................................................15
5STUDY  PROCEDURES AND ASSESSMENTS .............................................................16
5.1 Visits and Examinations ....................................................................................16
5.1.1 Visit 1 (Day  1) –Baseline/Dispense Study  Lens 1 ............................
16
5.1.2 Visit 2 (6 Day s ± 1 Day ) –Follow -up Study  Lens 1 / Dispense Study  
Lens 2 ................................................................................................18
5.1.3 Visit 3 (6 Day s ± 1 Day ) -Follow -up Study  Lens 2 / Exit Visit.......
[ADDRESS_582976] Evaluability ................................ ................................ ...........................23
6.2 Analy sis Data Sets ................................ ................................ .............................23
6.2.1 Safety  Analysis Set ................................ ................................ ............23
6.2.2 Full Anal ysis Set ................................ ................................ ................24
6.2.3 Per Protocol Anal ysis Set ................................ ................................ ..24
6.3 Demographic and Baseline Characteristics................................ .......................24
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017

Page 10of 44
6.4 Effectiveness Anal yses......................................................................................24
6.4.1 Primary  Effectiveness ........................................................................24
[IP_ADDRESS] Statistical Hy potheses ........................................................24
[IP_ADDRESS] Analy sis Methods ..............................................................25
6.4.2 Secondary  Effectiveness ................................ ................................ ....25
[IP_ADDRESS] Statistical Hy potheses ........................................................25
[IP_ADDRESS] Analy sis Methods ..............................................................[ADDRESS_582977] (IRB) ................................ ................................ .....39
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582978] ORY..........................................................................40
12REFERENCES ..................................................................................................................40
12.1
References applicable for all clinical trials: ......................................................40
12.1.1
US references applicable for clinical trials:.......................................[ADDRESS_582979] of Figur es
Figure 7–1 Categorization of All AEs................................ ................................ ................31
Figure 7-2 Categori zation of All Serious Adverse Events ................................ .................31
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017
Page 12of 44
3INTRODUCTION
3.1 Study Rationale and Purpose
Daily  disposable (DD) lenses are worn for a full day , during waking hours, and then thrown 
away  after usage. This modality  of contact [CONTACT_456098] y preferable by [CONTACT_456099], but not limited to, patients who 
have env ironmental allergies, patients who have excessive deposition of their non -DDlenses, 
younger patients where the ey e care professional and/or the parent are unsure of the patient’s 
ability  to remove and clean a set of lenses on a daily  basis, or patients who simply  prefer not 
to use a daily  cleaning and storage regimen.
New silicone h ydrogel ( SiHy ) materials continue to be developed and each of these contains 
a unique set of properties. A new DD SiHy  lens, known here as DD T2, has been developed 
that combine s high ox ygen transmissibility  with a low modulus of elasticity .
In this clinical trial, the overall lens performance of the study  lenses including VA  
 be assessed in a crossover design. The stud y lenses will be worn 
bilaterally  and in a DD wear modalit y for approximately [ADDRESS_582980] 
development . There are no immediate plans to submit the results of this study  for publication; 
however, the results may be offered for publication if they  are of scientific interest, or if the 
results relate to a product that is subsequently  approved or cleared for m arketing. The design 
of this study  is justified based 
upon preclinical and clinical testing, as described within the 
Investigator’s Brochure (IB).
3.2 Trial Objective
The primary  objective of this study  is to demonstrate noninferiorit y in VAof DD T2 when 
compared to 
MYDAY . 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582981] results, DD 
T2are assessed to be non- toxic and biocompatible for on -eye use. 
MYDA Yisfor dail y wear use under a DDwear modality ; further details on any known 
potential risks and benefits can be found in the package insert .Refer to Appendix , Section 13.
DD T2 andMYDA Y are not intended for use with a cleaning/ disinfecting solution, and the 
biocompatibility  with lens care solutions and an y associated clinical ef fects are unknown.
A summary  of the known potential risks and benefits associated with DD T2 can be found in 
the IB.Risks are minimized by [CONTACT_69204], 
andthrough close supervision by  a licensed clinician during exposure to the study  lenses. The 
potential harms associated with on
-eye exposure to the new lens materia ls include toxicity  
response, blurred vision and ocular discomfort. In general, the risks with DD T2 are 
anticipated to be similar to other marketed DDsoft contact [CONTACT_13276]. 
Site personnel will educate subjects on proper h ygiene and lens handling, and comp liance 
with the use of contact [CONTACT_13287] . Subjects should be instructed not to 
wear contact [CONTACT_13288][INVESTIGATOR_13263]. Site personnel will also advise the subjects 
to remove contact [CONTACT_13289] -up of s ymptoms, such as ocular 
discomfort, foreign bod y sensation, excessive tearing, vision changes, or h yperemia .
3.[ADDRESS_582982] of 
subjects with normal ey es (other than the need for optical 
correction for myopia), who are 
adapted, existing wearers of soft contact [CONTACT_94636](excluding previous or current MYDA Y
wearers) in both ey es.To qualify , subjects must require contact [CONTACT_456100] a power range from 
-1.[ADDRESS_582983] of inclusion/exclusion criteria in Section 1
of this protocol. Rescreening of subjects is not allowed in this study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_582984] u d y  is e x pecte d t o be c o m plete d i n a p pr o xi matel y  
1m o nt h .T he ef fecti ve ness a n d safet y assess me nts al o n g wit h t heir c ollecti o n ti me p oi nts are 
prese nte d i n T a ble 1 - 1. 
4T R E A T M E N T S A D MI NI S T E R E D 
S u b jects will be ra n d o mize d i n a 1 : 1 ma n ner t o recei ve t reat me nt i n a cr oss o ver se q ue nce: 
Te st pr o d uct t he n C o ntr ol pr o d uct or C o ntr ol pr o d uct t he n Te st pr o d uct, res pecti vel y .
4. [ADDRESS_582985] u d y Tr e at me nts 
D E S C RI P TI O N O F  T E S T  A N D C O N T R O L  P R O D U C T S 
T E S T C O N T R O L 
Le ns D D T 2 M Y D A Y
Material ste nfilc o n A
Wa ter C o nte nt 5 1 % 5 4 % 
Base C ur ve ( m m) 8. 3 8. 4 
Dia meter ( m m) 1 4. 2 1 4. 2 
R x p o wers ( D) t o be 
a vaila ble i n t his st u d y -1. 5 0 t o - 4. 0 0 ( 0. 2 5 ste ps) - 1. 5 0 t o - 4. 0 0 ( 0. 2 5 ste ps) 
Pac ka gi n g, La beli n g, a n d 
S u p pl y Blister f oil pac k 
F oil la bel i ncl u des: 
-material na me a n d 
i de ntifier 
-base c ur ve 
-dia meter 
-ma n ufact uri n g 
pr ot oc ol n u m ber 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pi[INVESTIGATOR_1313] o n date 
-c o nte nt state me nt 
-i n vesti gati o nal Blister f oil pac k 
C o m mercial f oil wit h 
Half O ver -la bel 
-material na me 
-base c ur ve 
-dia meter 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pi[INVESTIGATOR_1313] o n date 
-c o nte nt state me nt 
-i n vesti gati o nal 
de vice state me nt 
-c o u ntr y  of ori gi n. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 1 5 of 4 4 
de vice state me nt 
-s p o ns or 
i nf or mati o n 
-c o u ntr y  of ori gi n. 
Pr o vi de d i n b o xes of 1 0 
le nses per p o wer per b o x, 
i de ntifie d wit h t he 
f oll o wi n g: 
-a la bel stati n g t he 
pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal 
use o nl y  state me nt 
-trac ki n g n u m ber. 
Le nses s h o ul d be st ore d at 
r o o m te m perat ure. Pr o vi de d i n b o xes of 1 0 
le nses per p o wer per b o x, 
i de ntifie d wit h t he 
f oll o wi n g: 
-a la bel stati n g t he 
pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal 
use o nl y  state me nt 
-trac ki n g n u m ber. 
Le nses s h o ul d be st ore d 
at r o o m te m perat ure. 
Usa ge Wear: 
oDail y  Wear 
oBilateral, Cr oss o ver 
Re place me nt peri o d: D D 
E x p os ure: At least [ADDRESS_582986] u d y  d urati o n , 6- d a y ( ± 1 da y )wi n d o w per pr o d uct 
Le ns Care: N/ A 
4. 2 Acc o u nt a bilit y Pr oce d ures Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_582987] u d y  m o nit or f or t he p ur p oses of verif y i n g t he acc o u nti n g of cli nical 
s u p plies. A n y discre pa ncies a n d/ or deficie ncies bet wee n t he o bser ve d dis p ositi o n a n d t he 
writte n acc o u nt m u st be rec or de d al o n g wit h a n e x pla nati o n. 
It is t he I n vesti gat or ’s  res p o nsi bilit y  t o e ns ure t hat: 
Pa ge 1 6 of 4 4 
All st u d y  pr o d ucts are acc o u nte d f or a n d n ot use d i n a n y  u na ut h orize d ma n ner 
All use d f oils a n d u n use d s u p plies are ret ur ne d b y eac h s u bject 
All u n use d pr o d u cts are a vaila ble f or ret ur n t o t he St u d y  S p o ns or , as directe d 
A n y  st u d y  le nses ass ociate d wit h a de vice deficie nc y  or wit h a n y  pr o d uct -relate d 
a d verse e ve nt [ie, A D E or S A D E ]are ret ur ne d t o t he St u d y  S p o ns or f or i n vesti gati o n. 
Refer t o Secti o n 7. [ADDRESS_582988] u d y  pr o d ucts ass ociate d wit h t hese 
e ve nts. 
5S T U D Y  P R O C E D U R E S A N D A S S E S S M E N T S 
5. 1 Vi sits a n d E x a mi n ati o ns 
5. 1. 1 Vi sit 1 ( D a y 1) –B aseli ne/ Dis pe nse St u d y Le ns [ADDRESS_582989]’s c hart. After si g ni n g 
t he I C F , a s u bject will be assi g ne d a s u bject n u m ber b y  t he E D C s y ste m . A si g ne d 
i nf or me d c o nse nt d oc u me nt defi nes t he p oi nt of e nr oll me nt. 
[ADDRESS_582990] 3 0 da y s. I ncl u de her bal t hera pi[INVESTIGATOR_014], vita mi ns, a n d all 
o ver -t he -c o u nter as well as prescri pti o n me dicati o ns. 
3
4 Perf or m S nelle n V A wit h ha bit ual c orrecti o n .
 O D , O S, dista nce o nl y,  c o ntact le nses *
 Rec or d ha bit ual le ns i nf or mati o n ( bra n d, p o wer). 
* Rec or d i n S o urce D oc u me nt o nly. 
5
6Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 1 7 of 4 4 
7 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he f oll o wi n g: 
 Li m bal h y pere mia 
 B ul bar h y p ere mia 
 C or neal stai ni n g 
 C o nj u ncti val stai ni n g 
 C or neal vasc ularizati o n 
 C or neal e pit helial e de ma 
 C or neal str o mal e de ma 
 C o nj u ncti val c o m pressi o n/i n de nti o n 
 C he m osis 
 Pal pe bral c o nj u ncti val o bser vati o ns 
 C or neal i nfiltrates 
 Ot her fi n di n gs 
8  
9 Re vie w i ncl usi o n/e xcl usi o n criteria t o deter mi ne if t he s u bject q ualifies t o be 
ra n d o mize d i nt o t he st u d y . I f s u bject q ualifies, re q uest ra n d o mizati o n. 
[ADDRESS_582991] u d y  le nses .  
Kee p all li d di n g f oils of le nses use d d uri n g le ns fit pr ocess f or st u dy le ns 
acc o u nt a bility. 
F oll o w pr oce d ures t o m ai nt ai n m aski n g. 
[ADDRESS_582992] u d y le nses b y perf or mi n g t he f oll o wi n g: 
  S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) * *
O ver -refracti o n if necessar y  t o deter mi ne t he best c o ntact le ns- c orrecte d V A 
a n d fi nal st u d y  le ns p o wer(s) 
* * V A w/st u dy le nses m ust be 2 0/ [ADDRESS_582993] t he office Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_582994] u d y  visit. 
N ote: A Es a n d device deficie ncies m ust be rec or de d f or all e nr olle d s u bjects fr o m t he ti me of 
si g n at ure of i nf or me d c o nse nt i ncl u di n g t h ose t h at scree n f ail. 
16Dis pe nse st u d y  le nses a n d i nstr uct t he s u bject o n le ns wear. 
17Sc he d ule Visit [ADDRESS_582995] 6 da y s ( ± 1 da y )after Visit 1. 
5. 1. 2 Vi sit 2 ( 6 D a y s± 1 D a y) – F oll o w- u p St u d y Le ns 1/ Dis pe nse St u d y 
Le ns 2
1 O btai n i nf or mati o n o n a n y  c ha n ges i n me dical healt h a n d/ or t he use of 
c o nc o mita nt me dicati o ns. 
2 Rec or d a n y de vice deficie ncies or A Es t hat are o bser ve d or re p orte d, i ncl u di n g 
t h ose ass ociate d wit h c ha n ges i n c o nc o mita nt me di cati o n d osi n g si nce t he 
pre vi o us visit(s). 
[ADDRESS_582996] u d y  le nses b y  perf or mi n g t he f oll o wi n g: 
 S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) 
N ote: Perf or m B C V A if t here is a decre ase of V A by 2 li nes or m ore wit h I P Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_582997] u d y  le nses .
9 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he 
f oll o wi n g: 
 Li m bal h y pere mia 
 B ul bar h y p ere mia 
 C or neal stai ni n g 
 C o nj u ncti val stai ni n g 
 C or neal vasc ularizati o n 
 C or neal e pit helial e de ma 
 C or neal str o mal e de ma 
 C o nj u ncti val c o m pressi o n/i n de nti o n 
 C he m osis 
 Pal pe bral c o nj u ncti val o bser vati o ns 
 C or neal i nfiltrates 
 Ot her fi n di n gs 
[ADDRESS_582998] u d y  le nses t o be e val uate d .
Kee p all li d di n g f oils of le nses use d d uri n g le ns fit pr ocess f or st u dy le ns 
acc o u nt a bility. 
F oll o w pr oce d ures t o m ai nt ai n m aski n g. 
[ADDRESS_582999] u d y le nses b y perf or mi n g t he f oll o wi n g: 
 S nelle n V A wit h st u d y le nses ( O D a n d O S, at dista nce) * 
O ver -refracti o n if necessar y  t o deter mi ne t he best c o ntact le ns -c orrecte d 
V A a n d fi nal st u d y le ns p o wer(s) 
*V A w/st u dy le nses m ust be 2 0/ [ADDRESS_583000] t he office Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_583001] 6 da y s± 1d a y  after Visit 2. 
5. 1. 3 Vi sit 3 ( 6 D a y s± 1 D a y) -F oll o w -u p St u d y Le ns 2 / E xit Vi sit 
1 O btai n i nf or mati o n o n a n y  c ha n ges i n me dical healt h a n d/ or t he use of c o nc o mita nt 
me dicati o ns. 
2 Rec or d a n yde vice deficie ncies or A Es t hat are o bser ve d or re p orte d, i ncl u di n g t h ose 
ass ociate d wit h c ha n ges i n c o nc o mita nt me dica ti o n d osi n g si nce t he pre vi o us 
visit(s) .
[ADDRESS_583002] u d y le nses b y perf or mi n g t he f oll o wi n g: 
 S nelle n V A  wit h st u d y  le nses ( O D a n d O S, at dista nce) 
N ote: Perf or m B C V A if t here is a decre ase of V A by [ADDRESS_583003] u d y  le nses .Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 2 1 of 4 4 
9 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he f oll o wi n g: 
 Li m bal h y pere mia 
 B ul bar h y p ere mia 
 C or neal stai ni n g 
 C o nj u ncti val stai ni n g 
 C or neal vasc ularizati o n 
 C or neal e pit helial e de ma 
 C or neal str o mal e de ma 
 C o nj u ncti val c o m pressi o n/i n de nti o n 
 C he m osis 
 Pal pe bral c o nj u ncti val o bser vati o ns 
 C or neal i nfiltrates 
 Ot her fi n di n gs 
10 Perf or m S nelle n V A wit h ha bit ual c orrecti o n * .
 O D , O S, dista nce o nl y
 O ver -refracti o n ( o nl y nee de d if V A is re d uce d) 
* Rec or d i n s o urce d oc u me nt o nly 
11E xit t he s u bject fr o m t he st u d y .
5. 2 U nsc he d ule d Vi si ts Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_583004] t he f oll o wi n g pr oce d ures: 
Pa ge 2 2 of 4 4 
C ollect A E a n d De vice Deficie nc y i nf or ma ti o n 
Assess a n d r ec or d c ha n ges i n me dical c o n diti o n or c o nc o mita nt me dicati o n 
Asse ss a n d rec or d V A s
Perf or m b i o micr osc o p y (assess me nts wit h or wit h o ut le nses, as a p plica ble) 
T he I n vesti gat or ma y  perf or m a d diti o nal pr oce d ures f or pr o per dia g n osis a n d treat me nt of t he 
s u bject. T he I n vesti gat or m ust d oc u me nt t his i nf or mati o n i n t he s u bject’ s case hist or y  s o urce 
d oc u me nts. 
If d uri n g a n U nsc he d ule d V isit t he s u bject is disc o nti n ui n g t he st u d y  le nses or disc o nti n ui n g 
fr o m t he st u d y , t he I n vesti gat or m ust c o n d uct E xit pr oce d ures acc or di n g t o Ta ble 1 - 1: 
Sc he d ule of St u d y  Pr oce d ures a n d Assess me nts , as p ossi ble .
5. [ADDRESS_583005] d (ie, t heir s u bject n u m bers will n ot be 
re -assi g ne d/re -use d). 
S h o ul d a s u bject e x hi bit a n y  cli nicall y  rele va nt si g ns, s y m pt o ms, or ot her cli nical 
o bser vati o ns t hat p ossi bl y  c o ul d be ass ociate d wit h s us pecte d se nsiti vit y  or i nt olera nce t o o ne 
of t he st u d y  treat me nts, t he I n vesti gat or m ust d oc u me nt t h ose o bser vati o ns o n a n A E F or m. 
A n y  s u bject w h o e xits earl y  fr o m t he st u d y  m ust u n der g o all pr oce d ures o utli ne d at Visit 3, 
as a p plica ble .
T he I n vesti gat or m ust d oc u me nt t he reas o n f or st u d y  or treat me nt disc o nti n uati o n i n t he 
s u bject’ s case hist or y  s o urce d oc u me nts. 
To  e ns ure t he safet y of all s u bjects w h o disc o nti n ue earl y,  I n vesti gat ors m ust assess eac h 
s u bject a n d, if necessar y , a d vise t he m of a n y t hera pi[INVESTIGATOR_014] a n d/ or me dical pr oce d ures t hat m a y  be 
nee de d t o mai ntai n t heir healt h. 
5. [ADDRESS_583006] u d y Te r mi n ati o n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_583007] u d y S p o ns or: 
T he St u d y  S p o ns or m ust: 
oI m me diatel y  n otif y  t he I n vesti gat or(s) a n d s u bse q ue ntl y  pr o vi de 
i nstr ucti o ns f or st u d y  ter mi nati o n. 
oI n f or m t he I n vesti gat or a n d t he re g ulat or y  a ut h orities of t he 
ter mi nati o n/s us pe nsi o n a n d t he reas o n(s) f or t he ter mi nati o n/s us pe nsi o n, 
as a p plica ble . 
T he I n vesti gat or m ust: 
oPr o m ptl y  n otif y  t he I R Bof t he ter mi nati o n or s us pe nsi o n a n d of t he 
reas o ns. 
oPr o vi de s u bjects wit h rec o m me n dati o ns f or p ost -st u d y  treat me nt o pti o ns 
as nee de d. 
T he I n vesti gat or ma y  ter mi nate asite’ s partici pati o n i n t he st u d y  f or reas o na ble ca use. 
6A N A L Y SI S P L A N 
C o nti n u o us varia bles will be s u m marize d usi n g t he n u m ber of o bser vati o ns, mea n, sta n dar d 
de viati o n, me dia n, mi ni m u m, a n d ma xi m u m. Cate g orical varia bles will be s u m mari ze d wit h 
c o u nts a n d perce nta ges fr o m eac h cate g or y . A n y de viati o ns t o t his a nal y sis pla n will be 
u p date d d uri n g t he c o urse of t he st u d y as part of a pr ot oc ol a me n d me nt or will be detaile d i n 
t he cli nical st u d y  re p ort. 
6. [ADDRESS_583008] e val ua bilit y  will be deter mi ne d pri or t o brea ki n g t he c o de f or mas ke d 
treat me nt (le ns) se q ue nce assi g n me nt a n d l oc ki n g t he data base, base d u p o n t he De viati o ns 
a n d E val ua bilit y  Pla n ( D E P) .
6. 2 A n al ysis D at a Sets 
6. 2. 1 S afet y A n al ysis Set Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Safet y  a nal ys es will be c o n d ucte d usi n g t he safet y a nal ys is set o n a treat me nt -e mer ge nt basis. 
As s uc h, t he safet y  a nal ysis set will i ncl u de all s u bjects/e yes e x p ose d t o a n y st u d y le nses 
e val uate d i n t his st u d y . F or treat me nt -e mer ge nt safet y a nal ys es, s u bjects/e yes will be 
cate g orize d u n der t he act ual st u d y  le nses e x p ose d. 
Page 24of 44
6.2.2 Full Analysis Set
The full analysis set (FAS) is the set of all randomized subjects who are exposed to any  study  
lenses evaluated in this study . 
6.2.3 Per Protocol Analysis Set
The per protocol (PP) analy sis set is a subset of F AS and excludes all data which have met 
any of the critical deviation or evaluability  criteria identified in the DEP . 
6.3 Demographic and Baseline Characteristics
Demographic information (age, sex, ethnicity , race) will be summarized on the safety , full, 
and PP  analy sis set s. Baseline data pertaining to habitual lens (lens brand, power ,  
) will be summarized on the full and PP  analy sis sets. 
6.4 Effectiveness Analyses
This study  defines one primary  effectiveness endpoint,  
 The F AS will serve as the primary  set for all 
effectiveness anal yses.  
 
 
 
6.4.1 Primary Effectiveness
The primary  objective of this study  is to demonstrate noninferiorit y in VAof DD T2 when 
compared to 
MYDA Y.
The primary  endpoint is VA(logMAR) at Dispense and W eek 1 , Follow -Up. 
[IP_ADDRESS] Statistical Hypotheses
The null and alternative hy potheses are formulated in terms of the predefined margin of 0.05 
for noninferiority : 
H0: µ(DDT2) - µ(MYDA Y)≥  0.05
Ha: µ(DDT2) - µ(MYDA Y)<  0.05
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017

Page 25of 44
where µ (DDT2) and µ (MYDA Y)denote the mean VAfor DD T2 and MYDA Y, respectively . 
[IP_ADDRESS] Analysis Methods
A mixed ef fect repeated measures m odel will be utilized to test these hy potheses. The model 
will include terms for lens, visit, lens by  [CONTACT_23259], period, and sequence. Within-
subject correlation due to eye and the crossover will also be accounted for in the model. Lens 
difference (DD T2 minus MYDA Y) and the corresponding one- sided 95% upper confidence 
limit will be computed. Noninferiorit y in VAwill be declared if upper confidence limit is less 
than 0.05.
6.4.2 Secondary Effectiveness
Not applicable.
[IP_ADDRESS] Statistical Hypotheses
Not applicabl e.
[IP_ADDRESS] Analysis Methods
Not applicable.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583009] on the 
results in this study . No subgroup anal yses are planned.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017

Page 27of 44
6.6 Handling of Missing Data
All data obtained in evaluable subjects/ey es will be included in the analy sis. No imputation 
for missing values will be carried out for the primary  anal ysis.
6.8 Safety Analysis
The safet y endpoints for this study  are AEs, biomicroscop y findings, and device deficiencies. 
Descriptive summaries (counts and percentages) for ocular and nonocular AEs will be 
presented b y Medical Dictionary  for Regulatory  Activities Preferred T erms. AEs leading to 
study  discontinuation, significant nonserious AEs, and SAEs will be identified. Individual 
subject listings will be provided, as necessary . 
Individual subject listings will be provided for AEs that occur after signing informed consent 
but prior t o exposure to study  lenses . This listing will include the following variables: lens 
sequence assigned, Investigator , subject, age, sex, ey e (if ocular), in addition to relevant data 
describing the AE.  
Each biomicroscop y parameter will be tabulated by [CONTACT_456101]. For each biomicroscop y 
parameter , counts and percentages of ey es that experience an increase of ≥ 2 grades from 
baseline (V isit 1) to any  subsequent visit within the specific crossover period will be 
presented. A supportive listing will be generate d which will include all biomicroscopy  data 
from all visits within the af fected period for these ey es experiencing the increase, with the 
following variables: lens, I nvestigator , subject, age, sex, visit, ey e, parameter , baseline value, 
and value at the vi sit.
Two listings (prior to exposure of stud y lenses and treatment -emergent) of device 
deficiencies, as recorded on the Device Deficiency Form, will be provided. Additionally , each 
device deficiency  category  will be tabulated. Each listing will include the following 
variables: lens, Investigator, subject, age, sex, in addition to relevant data describing the 
device deficiency  and associated ADE , if an y. 
No inferential testing will be done for safet y anal ysis. 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583010] an interim anal ysis and no criteria b y which the study would be 
terminated early  based upon statistical determination. 
7ADVERSE EVENTS AND DEVICE DEFICIENCIES
Terms and Definitions
Adverse Event (AE) Any untoward medical occurrence, unintended disease or injury , or 
untoward clinical signs (including abnormal laboratory  findings) in 
subjects, users or other persons, whether or not related to the 
investigational medical device (test article). Note: For subjects, 
this definition includes events r elated to the test article, the contr ol 
article, or the pr ocedur es involved. For users or other persons, 
this definition is restricted to events r elated to the test article.
Adverse Device 
Effect (ADE)AErelated to the use of an investigational medical device (test 
article) or control article. Note: This definition includes AEs
resulting fr om insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation; any 
malfunction; and use err or or intentional misuse of the test article 
or contr ol article.
Anticipated Serious 
Adverse Device 
Effect (ASADE)Serious ADE which b y its nature, incidence, severity  or outcome 
has been identified in the risk management file.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583011] t o its i de ntit y , q ualit y , 
d ura bilit y , relia bilit y , safet y , or perf or ma nc e. N ote: T his defi niti o n 
i ncl u des m alf u ncti o ns, use err ors, a n d i n a de q u ate l a beli n g. 
Malf u ncti o n Fail ure of a me dical de vice t o meet its perf or ma nce s pecificati o ns 
or ot her wise perf or m as i nte n de d. Perf or ma nce s pecificati o ns 
i ncl u de all clai ms ma de i n t he la beli n g of t he de vice. T he i nte n de d 
perf or ma nce of t he de vice refers t o t he i nte n de d use f or w hic h t he 
de vice is la bele d or mar kete d. 
N o nseri o us A d verse 
E ve nt A E t hat d oes n ot meet t he criteria f or a nS A E .
Seri o us A d verse 
E ve nt ( S A E) A E t h at le d t o a n yof t he f oll o wi n g: 
Deat h. 
A seri o us deteri orati o n i n t he healt h of t he s u bject t hat eit her 
res ulte d i n: 
a) a life -t hreate ni n g ill ness or i nj ur y .
N ote: Life -t hr e ate ni n g me a ns t h at t he i n divi d u al w as at 
i m me di ate risk of de at h fr o m t he eve nt as it occ urr e d, ie, it 
d oes n ot i ncl u de a n eve nt w hic h hy p ot hetic ally mi g ht h ave 
c a use d de at h h a d it occ urr e d i n a m or e sever e f or m. 
b) a n y  p ote ntiall y  si g ht -t hreate ni n g e ve nt or per ma ne nt 
i m pair me nt t o a b o d y  str uct ure or a b o d y  f u ncti o n. 
c) i n -patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n ge d h os pi[INVESTIGATOR_1314] o n. 
N ote: Pl a n ne d h os pit aliz ati o n f or a pr e- existi n g c o n diti o n, 
wit h o ut seri o us deteri or ati o n i n he alt h, is n ot c o nsi der e d 
a n S A E . I n ge ner al, h os pit aliz ati o n si g nifies t h at t he 
i n divi d u al r e m ai ne d at t he h os pit al or e mer ge ncy w ar d f or 
o bser v ati o n a n d/ or tr e at me nt ( us u ally i nv olvi n g a n 
over ni g ht st ay) t h at w o ul d n ot h ave bee n a p pr o pri ate i n t he 
p hysici a n's office or a n o ut -p atie nt setti n g. C o m plic ati o ns 
t h at occ ur d uri n g h os pi t aliz ati o n ar e a dverse eve nts. If a 
c o m plic ati o n pr ol o n gs h os pit ali z ati o n or f ulfills a ny ot her 
seri o us criteri a, t he eve nt is seri o us. W h e n i n d o u bt as t o 
w het her “ h os pit aliz ati o n ” occ urr e d, t he eve nt s h o ul d be 
c o nsi der e d seri o us. 
d) a me dical or s ur gical i nter ve nti o n t o pre ve nt a) or b). 
e) a n y  i n direct har m as a c o nse q ue nce of i nc orrect dia g n ostic 
test res ults w he n use d wit hi n ma n ufact urer ’s  i nstr ucti o ns Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pa ge 3 0 of 4 4 
f or use. 
Fetal distress, fetal deat h, or a c o n ge nital a b n or malit y  or birt h 
defect. 
Refer t o Secti o n 7. [ADDRESS_583012] 
( S A D E) A D E t hat h as res ulte d i n a n y  of t he c o nse q ue nces c haracteristic of 
a n S A E .
Si g nifica nt 
N o n seri o us A d verse 
E ve nt A si g nifica nt n o nseri o us A E is a s y m pt o matic, de vice -relate d, n o n -
si g ht t hreate ni n g A E t hat warra nts disc o nti n uati o n of a n y  c o ntact 
le ns wear f or greater t ha n or e q ual t o [ADDRESS_583013] 
( U S A D E) Seri o us a d verse de vice effect w hic h b y its nat u re, i nci de nce, 
se verit y or o utc o me has n ot bee n i de ntifie d i n t he ris k ma na ge me nt 
file. 
Use Err or Act or o missi o n of a n act t hat res ults i n a dif fere nt me dical de vice 
res p o nse t ha n i nte n de d b y ma n ufact urer or e x pecte d b y user. 
N ote: T his defi niti o n i ncl u des sli ps, l a pses, a n d mist akes. A n 
u nex pecte d p hysi ol o gic al res p o nse of t he s u bject d oes n ot i n itself 
c o nstit ute a use err or . 
7. 1 Ge ner al I nf or m ati o n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
A n A E is a n y u nt o war d me dical occ urre nce, u ni nte n de d disease or i nj ur y, or u nt o war d 
cli nical si g ns (i ncl u di n g a b n or mal la b orat or y  fi n di n gs) i n s u bjects, users, or ot her pers o ns, 
w het her or n ot relate d t o t he i n vesti gati o nal me dical de vice (test article). 
Pa ge 3 1 of 4 4 
Fi g ur e 7 – 1 C ate g oriz ati o n of All A Es 
Fi g ur e 7 - 2 C ate g oriz ati o n of All Seri o us A d verse E ve nts 
Seri o us A dverse Eve nts 
I n a d diti o n t o re p orti n g all A Es (seri o us a n d n o nseri o us) meeti n g t he defi niti o ns, t he 
I n vesti gat or m ust re p ort a n y  occ urre nce of t he f oll o wi n g as a n S A E: 
A n oc ular i nfecti o n i ncl u di n g a pres u me d i nfecti o us ulcer wit h a n y of t he f oll o wi n g 
c haracteristics: 
oCe ntral or parace ntral l ocati o n 
oAlc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Pe netrati o n of B o w ma n’ s me m bra ne 
Pa ge 3 2 of 4 4 
oI n filtrates > 2 m m dia meter 
oIritis 
oI n crease i n i ntra oc ular press ure 
oC ult ure p ositi ve f or micr o or ga nis ms 
oI n creasi n g size or se verit y  at s u bse q ue nt visits 
A n y  ce ntral or parace ntral c or neal e ve nt (s uc h as ne o vasc ularizati o n) t hat res ults i n 
per ma ne nt o pacificati o n 
H y p o p y o n 
H y p he ma 
Ne o vasc ularizati o n wit hi n t he ce ntral 6 m m of t he c or nea 
Per ma ne nt visi o n l oss as defi ne d b y l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
visit t hat fails t o res ol ve 
U veitis (a nteri or , i nter me diate, or p osteri or) 
C or neal a brasi o n affecti n g ≥ 5 0 % of c or neal s urface area 
Si g nific a nt N o n seri o us A dverse Eve nts 
A si g nifica nt n o n -seri o us A E is a s y m pt o matic, de vice -relate d, n o n -si g ht t hreate ni n g A E t hat 
warra nts disc o nti n uati o n of a n y c o ntact le ns wear f or greater t ha n or e q ual t o [ADDRESS_583014] re p ort a n y  occ urre nce of t he f oll o wi n g as a Si g nifica nt 
N o n seri o us A E :
Peri p heral n o n - pr o gressi ve n o n- i nfecti o us ulcers 
All s y m pt o matic c or neal i nfiltrati ve e ve nts 
C or neal stai ni n g sc ore greater t ha n or e q ual t o Gra de 3 [ Gra di n g scal e is base d u p o n 
I S O 1 1 9 8 0: 2 0 1 2 u nless ot her wise s pecifie d] 
Te m p orar y  visi o n l oss as defi ne d b y  l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
visit t hat persists f or 2 or m ore wee ks 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
Ne o vasc ularizati o n sc ore greater t ha n or e q ual t o G ra de 2 [ Gra di n g scale is base d u p o n 
I S O 1 1 9 8 0: 2 0 1 2 u nless ot her wise s pecifie d] 
Pa ge 3 3 of 4 4 
T he a b ove eve nts ar e b ase d u p o n t he c ate g ories pr ovi de d i n t he I S O 1 1 9 8 0 a n d t he U S F D A  
Pr e m arket N otific ati o n (5 1 0(k )) G ui d a nce D oc u me nt f or D aily W e ar C o nt act Le nses a n d 
C o nt act Le ns C ar e Pr o d ucts. 
Device Deficie ncies 
A de vice deficie nc y  is i na de q uac y  of a me dical de vice wit h res pect t o its i de ntit y , q ualit y , 
d ura bilit y , relia bilit y , safet y , or perf or ma nce. A de vice deficie nc y  ma y  or ma y  n ot be 
ass ociate d wit h patie nt har m (ie, A D E or S A D E); h o we ve r,  n ot all A D Es or S A D Es are d ue 
t o a de vice deficie nc y . T he I n vesti gat or s h o ul d deter mi ne t he a p plica ble cate g or y liste d i n t he 
De vice Deficie nc y  e C R F f or t he i de ntifie d or s us pect de vice deficie nc y  a n d re p ort a n y patie nt 
har m se paratel y . E xa m ples of de vi ce deficie ncies i ncl u de t he f oll o wi n g: 
Fail ure t o meet pr o d uct s pecificati o ns (e g, i nc orrect le ns p o wer/ dia meter/ base 
c ur ve/c ol or) 
Le ns cl o u d y
Le ns s urface/e d ge defect 
To r n le ns d uri n g ha n dli n g/i n pac k 
Pac ka gi n g deficit (e g, misla bele d pr o d uct )
S us pect p r o d uct c o nta mi nati o n 
Lac k of perf or ma nce 
7. [ADDRESS_583015] has ha d t he o p p ort u nit y  t o s p o nta ne o usl y me nti o n a n y 
pr o ble ms, t he I n vesti gat or s h o ul d i n q uire a b o ut A Es b y  as ki n g t he sta n dar d q uesti o ns: 
“ Ha ve y o u ha d a n y healt h pr o ble ms si nce y o ur last st u d y  visit?” 
“ Ha ve t here bee n a n y c ha n ges i n t he me dici nes y o u ta ke si nce y o ur last st u d y  visit?” 
A d diti o nall y , c ha n ges i n a ny pr ot oc ol -s pecific p ar a meters a n d/ or q uesti o n n air es e val uate d 
d uri n g t he st u d y are t o be re vie we d b y t he I n vesti gat or . A n y u nt o war d ( u nfa v ora ble a n d 
u ni nte n de d) c ha n ge i n a pr ot oc ol -s pecific p ar a meter or q uesti o n n air e r es p o nse Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
t hat is 
cli nicall y  rele va nt, i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or , is t o be re p orte d as a n A E. T hese 
cli nicall y  rele va nt c ha n ges will be re p orte d re gar dless of ca usalit y . 
Pa ge 3 4 of 4 4 
7. 3 Pr oce d ures f or Rec or di n g a n d Re p orti n g 
A Es are c ollecte d fr o m t he ti me of i nf or me d c o nse nt .A n y pre -e xisti n g me dical c o n diti o ns or 
si g ns/s y m pt o ms prese nt i n a s u bject pri or t o t he start of t he st u d y  (ie, bef ore i nf or me d 
c o nse nt is si g ne d) are n ot c o nsi dere d A Es i n t he st u d y  a n d s h o ul d be rec or de d i n t he Me dical 
Hist or y  secti o n of t he e C R F .
I n a d diti o n, te m p orar y  le ns a ware ness or vis ual c ha n ges d uri n g t he fitti n g pr oces s are n ot 
c o nsi dere d A Es if t he I n vesti gat or assesses t hat t he s y m pt o m(s) ca n reas o na bl y  res ol ve wit hi n 
t he a ntici pate d a da ptati o n peri o d. 
A D Es or S A Es are d oc u me nte d o n t he Seri o us A dverse Eve nt a n d A dverse Device 
Effect e C R F wit hi n 2 4 h o urs of t he I n ves ti gat or ’s  or site’ s a ware ness . 
De vice deficie ncies are d oc u me nte d o n t he Device Deficie ncy e C R F wit hi n 2 4 h o urs 
of t he I n vesti gat or ’s  or site’ s a ware ness . 
A pri nte d c o p y of t he c o m plete d Seri o us A dverse Eve nt a n d A dverse Device Effect 
a n d/ or Device Defic ie ncy e C R F m ust be i ncl u de d wit h pr o d uct ret ur ns. 
A d diti o nal rele va nt i nf or mati o n after i nitial re p orti n g m ust be e ntere d i nt o t he e C R F as 
s o o n as t he data bec o me a vaila ble. 
D oc u me nt a n y c ha n ges t o c o nc o mita nt me dicati o ns o n t he a p pr o priate e C R Fs. 
D oc u me n t all rele va nt i nf or mati o n fr o m Disc har ge S u m mar y , A ut o ps y  Re p ort, 
Certificate of Deat h ,etc, if a p plica ble, i n narrati ve secti o n of t he Seri o us A dverse 
Eve nt a n d A dverse Device Effect e C R F .
N ote: S h o ul d t he E D C s yste m bec o me n o n -o perati o nal, t he site m ust c o m plete t he 
a p pr o priate pa per Seri o us A dverse Eve nt a n d A dverse Device Effect a n d/ or Device Deficie ncy Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_583016] u d y  S p o ns or at 
ft w . me dical _safet y @ alc o n.c o m acc or di n g t o t he ti meli nes o utli ne d a b o ve; h o we ver , t he 
re p orte d i nf or mati o n m ust be e ntere d i nt o t he E D C s y ste m o nce it bec o mes o perati o nal. 
A n y  A Es a n d de vice deficie ncies f or n o n -st u d y  mar kete d de vices/ pr o d ucts will be c o nsi dere d 
a n d pr ocesse d as s p o nta ne o us (f ol l o wi n g t he p ost -mar ket vi gila nce pr oce d ures) a n d s h o ul d be 
c o m m u nicate d t o t he de vice’ s/ pr o d uct’ s ma n ufact urer as per l ocal re q uire me nts. 
St u d y  S p o ns or re prese ntati ves ma y  be c o ntacte d f or a n y  pr ot oc ol relate d q uesti o n. 
Page 35of [ADDRESS_583017]’ s medical records. The 
Investigator must also report all AEs and device deficiencies that could have led to a SADE 
according to the req uirements of regulatory  authorities or I RB/IEC.
Intensity and Causality Assessments
Where appropriate, the Investigator must assess the intensity  (severit y) of the AE based upon 
medical judgment with consideration of an
y subjective symptom(s), as defined b elow:
Intensity (Severity)
Mild An AE is mild if the subject is aware of but can easily  tolerate the sign or 
symptom.
Moderate An AE is moderate if the sign or s ymptom results in discomfort significant 
enough to cause interference with the subject’ s usual activities.
Severe An AE is severe if the sign or sy mptom is incapacitating and results in the 
subject’ s inability  to work or engage in their usual activities.
For every  AE in the study , the Investigator must assess the causalit y (Related or Not Related 
tothe medical device or study  procedure). An assessment of causality  will also be performed 
by [CONTACT_13302], as shown below:
Causality
Related An AE classified as related may  be either definitely  related or possibl y related 
where a direct cause and ef fect relationship with the medical device or study  
procedure has not been demonstrated, but there is a reasonable possibility  that 
the AE was caused by  [CONTACT_13303] y procedure.
Not Related An AE classified as not rel ated may  either be definitely  unrelated or simply  
unlikely  to be related (ie, there are other more likely  causes for the AE).
The Study  Sponsor will assess the AEs and may  upgrade the Investigator ’s assessment of 
seriousness and/or causality . The Study  Sponsor will notify  the Investigator of an y AEs that 
are upgraded from nonserious to serious or from unrelated to related.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583018] analysis
Alcon products associated with device deficiencies and/or product related AEs should be 
returned and must includ e the Complaint # which will be provided by  [CONTACT_13304] ’s Global Product Complaint Management Sy stem. These 
products should be returned to the Sponsor at the end of the study , unless instructed otherwise 
by [CONTACT_1034] . 
7.5Follow -
Up of Subjects with Adverse Events
The Investigator is responsible for adequate and safe medical care of subjects during the 
study  and for ensuring that appropriate medical care and relevant follow -up procedures are 
maintained after the study . 
The Investigator should provide the Study  Spon sor with any  new safet y information (which 
includes new AEs and changes to previousl y reported AEs) that may  affect the safet y 
evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from 
study , any  additional information rec eived at follow -up should be documented in the eCRFs 
up to study  completion (ie, database lock). 
Any additional data received up to [ADDRESS_583019] be 
documented and available upon the Study  Sponsor ’s request. All compla ints received after 
this time period will be considered and processed as spontaneous and should be 
communicated to the medical device’ s manufacturer as per local requirements.
The Investigator should also report complaints on non -Alcon products directly  tothe 
manufacturer as per the manufacturer ’s instructions or local regulatory  requirements.
7.6Pregnancy in the Clinical Study
Women of childbearing potential or women who are pregnant at the time of study  entry  are 
not excluded from participation. Pregna ncy should be included in the Medical History  section 
of the eCRF when a pregnant woman enters the study  or if a woman becomes pregnant 
during the stud y. Pregnancy  is not reportable as an AE; however , complications may  be 
reportable and will be decided on a case –by- case basis. 
8CONFIDENTIALITY ,BIAS AND MASKING
8.[ADDRESS_583020]’ s anony mity is maintained throughout the
course of the stud y. In particular , the Investigator m ust keep an enrollment log with
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583021] information. All documents submitted to the
Sponsor will identify  the subjects exclusively  by [CONTACT_13305]. No
other personall y identifying information should be transmitted to the Sponsor .
This study  is double -masked with subjects randomized to use both DD T2 and MYDA Y(in a 
randomized sequence) for the duration of the 2 -week treatment period . The Investigator , 
 and Sponsor personnel (other than site monitors, lead clinical site manager , 
person responsible f or generating the randomiz ation schedule , and unmasked clinical data 
managers) involved in reporting, obtaining, and/or reviewing the clinical evaluations will be 
masked to the identity  of the contact [CONTACT_13306]. This level of masking will be 
maintained throughout the conduct of the s tudy. Unmasking will occur only after all planned 
study  data have been validated, and the database locked
.Masked stud y personnel must avoid 
seeking information that may  compromise masking. Unmasked study  personnel must not 
disseminate information that is potentially  unmasking to any  masked personnel. The masked 
and unmasked site personnel must coordinate all study  activities as necessary  to protect 
masking and minimize bias during the trial.
8.[ADDRESS_583022] an appropriate Study Sponsor r epresentative prior to 
unmasking the information if there is sufficient time. Dependent upon the individual 
circumstances (ie, medical emergency ), the code may  be broken prior to contact [CONTACT_40066]. The Study  Sponsor must be informed of all cas es in which the code was 
broken and of the circumstances involved. Additionally , the Study  Sponsor may  be required 
to unmask the information in order to fulfill expedited regulatory  reporting requirements.
9DATA HANDLING AND ADMINISTRA TIVE REQUIREMENTS
9.[ADDRESS_583023] be determined in adva nce 
of starting the stud y. 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583024]: 
S u bject i de ntificati o n ( na me, se x, race/et h nicit y) 
D oc u me ntati o n of s u bject eli gi bilit y 
Date of i nf or me d c o nse nt 
Dates of visits 
D oc u me nta ti o n t hat pr ot oc ol s pecific pr oce d ures were perf or me d 
Res ults of st u d y  para meters, as re q uire d b y t he pr ot oc ol 
I P acc o u nta bilit y  rec or ds 
D oc u me ntati o n of A Es a n d ot her safet y para meters (if a p plica ble) 
Rec or ds re gar di n g me dical hist ories a n d t he use of c o n c o mita nt t hera pi[INVESTIGATOR_258755] t o a n d 
d uri n g t he st u d y
Date of st u d y  c o m pleti o n a n d reas o n f or earl y disc o nti n uati o n, if a p plica ble 
It is re q uire d t hat t he a ut h or of a n e ntr y  i n t he s o urce d oc u me nts be i de ntifia ble. Direct access 
t o s o urce d oc u me ntati o n ( me dical rec or ds) m ust be all o we d f or t he p ur p ose of verif y i n g t hat 
t he data rec or de d o n t he e C R F are c o nsiste nt wit h t he ori gi nal s o urce data. 
O nl y desi g nate d i n di vi d uals ma y  c o m plete t he e C R F s. T he e C R Fs will be s u b mitte d at 
re g ular i nter vals f oll o wi n g t he cli ni cal st u d y  visit sc he d ule. It is e x pecte d t hat all data 
re p orte d will ha ve c orres p o n di n g e ntries i n t he s o urce d oc u me nts . T he Pri nci pal I n vesti gat or 
is res p o nsi ble f or re vie wi n g a n d certif y i n g t hat t he e C R F s are acc urate a n d c o m plete. T he 
o nl y  s u bject i de nt ifiers rec or de d o n t he e C R F s will be s u bject n u m ber , a n d s u bject 
de m o gra p hic i nf or mati o n. 
9. [ADDRESS_583025]’ s s o urce 
data will be c o m plete d b y  t he site m o nit or t o e ns ure c o m plete ness a n d acc urac y . Ad diti o nal 
data clarificati o ns a n d/ or a d diti o ns ma y  be nee de d as a res ult of t he data clea ni n g pr ocess. 
Data clarificati o ns are d oc u me nte d a n d are part of eac h s u bject’ s e C R F s. 
9. 3 Re g ul at or y D oc u me nt ati o n a n d Rec o r ds Rete nti o n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
T he I n vesti gat or is re q uire d t o mai ntai n u p- t o -date, c o m plete re g ulat or y  d oc u me ntati o n as 
i n dicate d b y t he S p o ns or a n d t he I n vesti gat or ’s  files will be re vie we d as part of t he o n g oi n g 
Page 39of [ADDRESS_583026] be notified and suitable arrangements made for retention of study  records and 
source documents needed to comply  with national and interna tional regulations (generall y 
2years after discontinuing clinical development or after the lastmarketing approval).
10ETHICS AND COMPLIANCE
This trial will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki and the referenced directives , regulations, guidelines, and/or 
standards.
10.[ADDRESS_583027] the clinical study  in 
compliance with the protocol. Deviations from this protocol, regulatory  requirements and/or 
GCP  must be recorded and reported to the Sponsor prior to database lock. If needed, 
corrective and preventive action should be identified, implemented, and documented within
thestudy  records.
10.[ADDRESS_583028] (IRB)
This trial requires IRB approval prior to initiation. This protocol, subject informed consent, 
and subsequent amendme nts will be reviewed and approved b y an IRB.
Before clinical study  initiation, this protocol, the ICF(and assent form, if applicable), an y 
other written information given to subjects, and any  advertisements planned for subject 
recruitment must be approved by [CONTACT_2717]. The Investigator must provide documentation of 
the IRBapproval to the Study  Sponsor . The approval must be dated and must identify  the 
applicable protocol, amendments (if an y), ICF, assent form (if an y), all applicable recruiting 
materials, wri tten information for subject, and subject compensation programs. The IRBmust 
be provided with a cop y of the IB, any periodic safety updates, and all other information as 
required b y local regulation and/or the IRB. At the end of the study , the Investigator must 
notify  the IRBabout the study ’s completion. The IRB also must be notified if the study  is 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_583029] (a n d/ or le gal re prese ntati ve, 
as a p plica ble) pri or t o t he i nitiati o n of a n y  scree ni n g or ot her st u d y -relate d pr oce d ures. T he 
I n vesti gat or m ust ha ve a defi ne d pr ocess f or o btai ni n g c o nse nt. S pecificall y , t he I n vesti gat or , 
or dele gate, m ust e x plai n t he cli nical st u d y  t o eac h p ote ntial s u bject a n d t he s u bject m ust 
i n dicate v ol u ntar y  c o nse nt b y  si g ni n g a n d dati n g t he a p pr o ve d i nf or me d c o nse nt f or m. T he 
s u bject m ust be pr o vi de d a n o p p ort u nit y  t o as k q uesti o ns of t he I n vesti gat or , a n d if re q uire d 
b y  l ocal re g ulati o n, ot her q ualifie d pers o n nel. T he I n vesti gat or m ust pr o vi de t he s u bject wit h 
a c o p y of t he c o nse nt f or m writte n i n a la n g ua ge t he s u bject u n dersta n ds. T he c o nse nt 
d oc u me nt m ust meet all a p plica ble l ocal la ws a n d pr o vi de s u bjects wit h i nf or mati o n 
re gar di n g t he p ur p ose, pr oce d ures, re q uire me nts, a n d restricti o ns of t he st u d y , al o n g wit h a n y  
k n o w n ris ks a n d p ote ntial be nefits ass ociate d wit h t he I P ,  t he a vaila ble c o m pe nsati o n, a n d t he 
esta blis he d pr o visi o ns f or mai ntai ni n g c o nfi de ntialit y  of pers o nal, pr otecte d healt h 
i nf or mati o n. S u bjects will be t ol d a b o ut t he v ol u ntar y  nat ure of partici pati o n i n t he st u d y  a n d 
m ust be pr o vi de d wit h c o ntact i nf or mati o n f or t he a p pr o priate i n di vi d uals s h o ul d q uesti o ns or 
c o ncer ns arise d uri n g t he st u d y . T he s u bject als o m ust be t ol d t hat t heir rec or ds ma y be 
accesse d b y a p pr o priate a ut h orities a n d S p o ns or -desi g nate d pers o n nel. T he I n vesti gat or m ust 
kee p t he ori gi nal, si g ne d c o p y  of t he c o nse nt a n d m ust pr o vi de a d u plicate c o p y  t o eac h 
s u bject acc or di n g t o l ocal re g ulati o ns. F oll o wi n g t his st u d y , t he s u bject will ret ur n t o t heir 
e y e care pr ofessi o nal f or t heir r o uti ne e y e care a n d c o ntact le nses. 
1 1 P R O T O C O L  A M E N D M E N T HI S T O R Y 
Versi o n Brief Descri pt i o n a n d R ati o n ale 
1 I nitial V ersi o n of t his d oc u me nt 
1 2 R E F E R E N C E S 
1 2. 1 Refere nces a p plic a ble f or all cli nic al tri als: 
I S O 1 1 9 8 0: [ADDRESS_583030] le ns care pr o d ucts -
G ui da nce f or cli nical i n vesti gati o ns 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
I S O 1 4 1 5 5: 2 0 1 1 Cli nical i n vesti gati o n of me dical de vices f or h u ma n s u bjects -G o o d 
cli nical practice 
Pa ge 4 1 of 4 4 
1 2. 1. 1 U S refere nces a p plic a ble f or cli nic al tri als: 
2 1 C F R Part 1 1 -Electr o nic Rec or ds; Electr o nic Si g nat ures 
2 1 C F R Part 5 0 -Pr otecti o n of H u ma n S u bjects 
2 1 C F R Part 5 6 - I n stit uti o nal Re vie w B oar ds 
2 1 C F R Part 8 1 2 - I n vesti gati o nal De vice E xe m pti o ns 
2 1 C F R Part 5 4 - Fi na ncial Discl os ure b y Cli nical I n vesti gat ors 
T he Calif or nia Bill of Ri g hts 
1 2. 2 Refere nces f or t his cli nic al tri al Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 3 4 2 8 P r o t o c o l  -  C l i n i c a l 0 7- Mar- 2 0 1 7 
N ot a p plica ble. 
Page 42of 44
13Appendix
13.1 MYDA YPack age Insert
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017
Page 43of 44
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017
Page 44of 44
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017
                                                                                                                
                                                                                     
Date/Time 
(mm/dd/yyyy GMT): Signed by: [CONTACT_13310] :
03/07/2017 03:02:55
03/06/2017 14:59:19
03/04/2017 00:05:07
03/04/2017 00:05:07
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0053428
Protocol - Clinical
07-Mar-2017
